Takeda Pharmaceutical Company has announced it will discontinue its cell therapy research and development efforts as part of a broader strategic portfolio prioritization. The company plans to seek an external partner to carry forward its cell therapy platform technologies and clinic-ready programs, despite having no active clinical trials currently underway in this area.
The decision marks a shift in Takeda’s near-term investment strategy, with the company choosing to concentrate on programs that promise faster and broader delivery of transformative treatments. Future focus will be on preclinical programs involving small molecules, biologics, and antibody-drug conjugates—areas the company considers to be its core therapeutic modalities.
Although cell therapy is being phased out internally, Takeda emphasized that the scientific insights and innovations gained through this research will continue to inform and enhance its ongoing preclinical work.
As a result of the decision, Takeda expects to record an impairment loss of approximately ¥58 billion in the second quarter of its fiscal year ending March 31, 2026. This loss is primarily tied to intangible assets linked to its gamma delta T-cell therapy platform. Most of the impact is expected to fall within the ¥50 billion in impairment losses already accounted for in Takeda’s full-year forecast for fiscal 2025, released on May 8, 2025.
The company said it will continue to review any further financial effects and will include any necessary adjustments in its second-quarter results and updated full-year forecast, which are scheduled to be released on October 30, 2025.